NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population

H. Eugene Liu, Pei Y. Hsiao, Ching Chen Lee, Jen A. Lee, Hsiang Y. Chen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Arylamine N-acetyltransferase-2 (NAT2) displays extensive genetic polymorphisms that affect the rates of acetylation of drugs and toxic compounds such as amine carcinogens. The association of NAT2 polymorphisms with adult brain tumors has been unclear. To investigate whether the NAT2 genotype is a risk factor of brain tumors, we determined the frequencies of three common polymorphisms in the NAT2 gene, NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7(G857A), in brain tumor patients and in age- and gender-matched control subjects (n = 27 in each group). Genotyping was carried out using PCR-RFLP and subjects were phenotyped as a fast or slow acetylator based on the genotypes. The odds ratio of NAT2*7 allele frequency was significantly higher in patients with brain tumor than in controls (odds ratio, 6.786; 95% confidence interval, 2.06-22.37; P = 0.003); in the mean time, NAT2*4/*7 genotype was significantly more common in the patient group than in controls (odds ratio, 6.19; 95% confidence interval, 1.68-22.79; P = 0.0039). The tumors in the patients with NAT2*7 allele tended to be high-grade astrocytoma or glioblastoma multiforme (P = 0.016). In conclusion, these data suggest that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan.

Original languageEnglish
Pages (from-to)661-665
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number3
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Acetyltransferases
Brain Neoplasms
Alleles
Population
Odds Ratio
Genotype
Arylamine N-Acetyltransferase
Confidence Intervals
Poisons
Astrocytoma
Genetic Polymorphisms
Glioblastoma
Acetylation
Taiwan
Gene Frequency
Restriction Fragment Length Polymorphisms
Carcinogens
Amines
Polymerase Chain Reaction
Control Groups

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population. / Liu, H. Eugene; Hsiao, Pei Y.; Lee, Ching Chen; Lee, Jen A.; Chen, Hsiang Y.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 17, No. 3, 03.2008, p. 661-665.

Research output: Contribution to journalArticle

@article{53119ab1e7324a4d911c65caccaadc19,
title = "NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population",
abstract = "Arylamine N-acetyltransferase-2 (NAT2) displays extensive genetic polymorphisms that affect the rates of acetylation of drugs and toxic compounds such as amine carcinogens. The association of NAT2 polymorphisms with adult brain tumors has been unclear. To investigate whether the NAT2 genotype is a risk factor of brain tumors, we determined the frequencies of three common polymorphisms in the NAT2 gene, NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7(G857A), in brain tumor patients and in age- and gender-matched control subjects (n = 27 in each group). Genotyping was carried out using PCR-RFLP and subjects were phenotyped as a fast or slow acetylator based on the genotypes. The odds ratio of NAT2*7 allele frequency was significantly higher in patients with brain tumor than in controls (odds ratio, 6.786; 95{\%} confidence interval, 2.06-22.37; P = 0.003); in the mean time, NAT2*4/*7 genotype was significantly more common in the patient group than in controls (odds ratio, 6.19; 95{\%} confidence interval, 1.68-22.79; P = 0.0039). The tumors in the patients with NAT2*7 allele tended to be high-grade astrocytoma or glioblastoma multiforme (P = 0.016). In conclusion, these data suggest that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan.",
author = "Liu, {H. Eugene} and Hsiao, {Pei Y.} and Lee, {Ching Chen} and Lee, {Jen A.} and Chen, {Hsiang Y.}",
year = "2008",
month = "3",
doi = "10.1158/1055-9965.EPI-07-2647",
language = "English",
volume = "17",
pages = "661--665",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - NAT2*7 allele is a potential risk factor for adult brain tumors in Taiwanese population

AU - Liu, H. Eugene

AU - Hsiao, Pei Y.

AU - Lee, Ching Chen

AU - Lee, Jen A.

AU - Chen, Hsiang Y.

PY - 2008/3

Y1 - 2008/3

N2 - Arylamine N-acetyltransferase-2 (NAT2) displays extensive genetic polymorphisms that affect the rates of acetylation of drugs and toxic compounds such as amine carcinogens. The association of NAT2 polymorphisms with adult brain tumors has been unclear. To investigate whether the NAT2 genotype is a risk factor of brain tumors, we determined the frequencies of three common polymorphisms in the NAT2 gene, NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7(G857A), in brain tumor patients and in age- and gender-matched control subjects (n = 27 in each group). Genotyping was carried out using PCR-RFLP and subjects were phenotyped as a fast or slow acetylator based on the genotypes. The odds ratio of NAT2*7 allele frequency was significantly higher in patients with brain tumor than in controls (odds ratio, 6.786; 95% confidence interval, 2.06-22.37; P = 0.003); in the mean time, NAT2*4/*7 genotype was significantly more common in the patient group than in controls (odds ratio, 6.19; 95% confidence interval, 1.68-22.79; P = 0.0039). The tumors in the patients with NAT2*7 allele tended to be high-grade astrocytoma or glioblastoma multiforme (P = 0.016). In conclusion, these data suggest that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan.

AB - Arylamine N-acetyltransferase-2 (NAT2) displays extensive genetic polymorphisms that affect the rates of acetylation of drugs and toxic compounds such as amine carcinogens. The association of NAT2 polymorphisms with adult brain tumors has been unclear. To investigate whether the NAT2 genotype is a risk factor of brain tumors, we determined the frequencies of three common polymorphisms in the NAT2 gene, NAT2*5 (T341C), NAT2*6 (G590A), and NAT2*7(G857A), in brain tumor patients and in age- and gender-matched control subjects (n = 27 in each group). Genotyping was carried out using PCR-RFLP and subjects were phenotyped as a fast or slow acetylator based on the genotypes. The odds ratio of NAT2*7 allele frequency was significantly higher in patients with brain tumor than in controls (odds ratio, 6.786; 95% confidence interval, 2.06-22.37; P = 0.003); in the mean time, NAT2*4/*7 genotype was significantly more common in the patient group than in controls (odds ratio, 6.19; 95% confidence interval, 1.68-22.79; P = 0.0039). The tumors in the patients with NAT2*7 allele tended to be high-grade astrocytoma or glioblastoma multiforme (P = 0.016). In conclusion, these data suggest that the presence of NAT2*7 allele might be a potential risk factor for the development of brain tumors in Taiwan.

UR - http://www.scopus.com/inward/record.url?scp=41549146564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549146564&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-07-2647

DO - 10.1158/1055-9965.EPI-07-2647

M3 - Article

C2 - 18349284

AN - SCOPUS:41549146564

VL - 17

SP - 661

EP - 665

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -